Literature DB >> 2499252

Changing susceptibility of Pseudomonas aeruginosa isolates from cystic fibrosis patients with the clinical use of newer antibiotics.

J A Bosso1, J E Allen, J M Matsen.   

Abstract

To detect a change in antibiotic susceptibility patterns in Pseudomonas aeruginosa isolates upon the introduction and clinical use of ciprofloxacin, aztreonam, and ceftazidime, MICs for clinical isolates collected before introduction of the antibiotics, during early clinical use, and later were determined for these and seven other antipseudomonal antibiotics. Concomitant resistance to two or more antibiotics was also studied. Over the three study periods, rates of susceptibility to 9 of the 10 antibiotics decreased. The largest decrease occurred with ceftazidime. Analysis of subsets of isolates from patients treated with ciprofloxacin or aztreonam also showed declining susceptibility to the latter but a stabilization of susceptibility to the former after an initial decline. Concomitant resistance within and among antibiotic classes was common.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2499252      PMCID: PMC172473          DOI: 10.1128/AAC.33.4.526

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.

Authors:  R Padoan; W Cambisano; D Costantini; R M Crossignani; M L Danza; G Trezzi; A Giunta
Journal:  Pediatr Infect Dis J       Date:  1987-07       Impact factor: 2.129

3.  Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.

Authors:  J A Bosso; P G Black; J M Matsen
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

4.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

5.  Azlocillin in respiratory tract infections with Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  H Michalsen; T Bergan
Journal:  Chemotherapy       Date:  1980       Impact factor: 2.544

6.  In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.

Authors:  S C Aronoff; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

7.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

8.  Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo.

Authors:  F J McLaughlin; W J Matthews; D J Strieder; B Sullivan; A Taneja; P Murphy; D A Goldmann
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226

9.  Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.

Authors:  R Gold; A Overmeyer; B Knie; P C Fleming; H Levison
Journal:  Pediatr Infect Dis       Date:  1985 Mar-Apr

10.  Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.

Authors:  J A Bosso; P G Black
Journal:  Pediatr Infect Dis J       Date:  1988-03       Impact factor: 2.129

View more
  6 in total

1.  Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.

Authors:  E Bingen; E Denamur; B Picard; P Goullet; N Lambert-Zechovsky; P Foucaud; J Navarro; J Elion
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

Review 2.  The emergence of antibiotic resistance: myths and facts in clinical practice.

Authors:  J M Hamilton-Miller
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils.

Authors:  Kim Thomsen; Lars Christophersen; Peter Østrup Jensen; Thomas Bjarnsholt; Claus Moser; Niels Høiby
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

4.  Marked phenotypic variability in Pseudomonas cepacia isolated from a patient with cystic fibrosis.

Authors:  G Y Larsen; T L Stull; J L Burns
Journal:  J Clin Microbiol       Date:  1993-04       Impact factor: 5.948

Review 5.  Microbiology of airway disease in patients with cystic fibrosis.

Authors:  P H Gilligan
Journal:  Clin Microbiol Rev       Date:  1991-01       Impact factor: 26.132

Review 6.  Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations.

Authors:  C A Lindsay; J A Bosso
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.